ArticleEuropean heart journal. Imaging methods and practice2026
Impact of myocardial perfusion abnormalities on clinical outcomes in patients treated with percutaneous coronary intervention for chronic total occlusions.
Article in European heart journal. Imaging methods and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Myocardial perfusion imaging (MPI) is used to evaluate ischaemia in patients with chronic total occlusion (CTO), but its prognostic implications following percutaneous coronary intervention (PCI) of CTO remain uncertain. Purpose: To evaluate outcomes in patients treated with CTO-PCI stratified by moderate-severe ischaemia on MPI prior to intervention. Methods and results: Patients from the Western Danish Heart Registry assessed by nuclear MPI and subsequently treated with CTO-PCI ≤ 6 months were included. Moderate-severe ischaemia was defined as ≥10% left ventricle involvement. Primary endpoints were all-cause mortality and a composite of major adverse cardio- and cerebrovascular events [MACCE; cardiovascular death, myocardial infarction (MI), stroke, and hospitalization for heart failure (HF) or angina pectoris]. Secondary endpoints included the individual MACCE components. Outcomes were compared between patients with and without moderate-severe ischaemia using multivariable Cox regression and competing risk regression at 90-day and 5-year follow-ups. Among 319 patients, 208 (65.2%) had moderate-severe ischaemia. All-cause mortality was similar between patients with and without moderate-severe ischaemia [adjusted hazard ratio (aHR) 1.12, 95% confidence interval (CI): 0.52-2.43], Conclusion: Moderate-severe ischaemia on nuclear MPI was not associated with differences in mortality or MACCE after CTO-PCI but was associated with a lower long-term risk of angina hospitalization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.